In the vocabulary of sleep medicine, “wakefulness” is not a mood. It can be timed with a test, scored on a scale and, Alkermes hopes, restored by nudging a receptor deep in the brain. The company's lead experimental medicine, alixorexton, is meant to activate the orexin system - the network that helps keep us awake. In phase 2 studies, adults with narcolepsy stayed awake longer on laboratory tests. By spring 2026, the medicine had moved into phase 3.
This is a sharp new chapter for a company whose old trick was making drugs linger. Alkermes grew up in drug delivery: polymer microspheres, tiny particles and formulations that released medicine slowly enough to turn a daily decision into a monthly injection. That expertise still runs through VIVITROL for alcohol and opioid dependence and ARISTADA for schizophrenia. But the company on the other side of 2026 is more focused, more commercial and much more interested in sleep.
A portfolio organized around burden
Alkermes works in conditions that can make consistency difficult just when consistency matters most. A person managing schizophrenia may miss a daily tablet. Someone recovering from opioid dependence may face a high-risk moment between appointments. A person with narcolepsy may be asked to wake in the middle of the night to take a second dose of an older oxybate treatment. The company's products are different, but their design briefs rhyme: reduce the friction between a medicine and the life around it.
VIVITROL is an extended-release injection given once a month. ARISTADA is a long-acting injectable available on schedules ranging from monthly to every two months, depending on dose. LYBALVI combines olanzapine, an established antipsychotic, with samidorphan in one daily tablet. LUMRYZ, acquired with Avadel Pharmaceuticals in February, is an extended-release sodium oxybate taken once at bedtime for cataplexy or excessive daytime sleepiness in narcolepsy.
The neuroscience map / marketed to experimental
The customer is therefore never simply “the patient.” Alkermes must persuade psychiatrists, addiction specialists and sleep physicians; navigate commercial and government payers; supply specialty pharmacies and wholesalers; train treatment sites; and support people through access and adherence. Long-acting injections require clinics that can store and administer them. LUMRYZ is distributed through a restricted safety program. In this market, the product includes a small operating system.
“Commitment to patients runs very deep at Alkermes. It starts when we discover new ideas in our labs.”Alkermes, on its approach to medicines
The sleep deal was also a distribution deal
Alkermes paid up to roughly $2.37 billion for Avadel, using about $775 million of cash and $1.525 billion of term loans. The obvious asset was LUMRYZ, launched in 2023 and approved for people age seven and older with narcolepsy. Its once-at-bedtime schedule is the practical distinction: earlier oxybate regimens generally require another dose during the night.
The less visible asset was a commercial team already calling on sleep specialists. Drug launches are exercises in accumulated trust and logistical memory. Avadel had prescriber relationships, patient services and rare-disease experience. Alkermes had alixorexton approaching late-stage trials. Put together, an approved medicine can open doors while an experimental one waits for data and regulators. It is vertical integration, only the vertical is a patient journey.
In July, Alkermes reported an interim analysis from an open-label extension study. Improvements on wakefulness and sleepiness measures were sustained through roughly nine months for participants with narcolepsy type 1 and type 2, and no serious treatment-emergent adverse events were reported in that analysis. These are encouraging company-reported data, not an approval. The phase 3 Brilliance studies are where the claim faces a larger test.
The orexin idea now extends beyond narcolepsy. ALKS 4510 is in phase 1 for fatigue associated with multiple sclerosis and Parkinson's disease. ALKS 7290 is in phase 1 for ADHD. Valiloxybate, inherited from Avadel, takes a different biological route and is in phase 1 for narcolepsy and idiopathic hypersomnia. A pipeline once described molecule by molecule now looks more like a map of alertness, attention and fatigue.
Three ways to make a dollar
The economic engine has three cylinders. First are sales of proprietary medicines in the United States. VIVITROL, ARISTADA and LYBALVI made up the core of 2025 product sales; LUMRYZ began contributing to Alkermes after the February 2026 acquisition. Second is manufacturing. The company makes three proprietary medicines at its Wilmington, Ohio, facility and manufactures selected products for partners. Third are royalties from technologies embedded in medicines sold by companies such as Johnson & Johnson and Biogen.
Total annual revenue / reported
That mix separates Alkermes from a single-asset biotech, but it also produces odd incentives. The company can compete against medicines that generate royalties for it. Its long-acting psychiatry products face alternatives from Johnson & Johnson even as J&J products use Alkermes technology. Heritage can be both moat and knot.
Against younger biotechs, Alkermes' advantage is infrastructure: medicinal chemistry and translational work near Boston, clinical development and medical affairs, an experienced U.S. commercial organization, market-access teams and GMP manufacturing in Ohio. Against global pharmaceutical groups, the company is smaller and more concentrated. It competes with Indivior and Braeburn in addiction; Otsuka, Lundbeck, Johnson & Johnson, Bristol Myers Squibb, AbbVie and generics in psychiatry; and Jazz, Harmony and Axsome in sleep. Its pitch is focus without fragility.
That places Alkermes between two familiar biotech archetypes. It is not a platform company offering a laboratory tool to anyone with a target, and it is not a virtual drug developer outsourcing nearly every function. Nor does it have the therapeutic sprawl of a global pharma conglomerate. It is a mid-sized specialist with enough of the value chain under one roof to make choices about formulation early and carry them into real clinics. That matters in central nervous system medicine, where a compound's usefulness can be shaped by dosing frequency, administration setting, side effects and the willingness of a payer to cover a complicated care pathway.
For health systems, Alkermes offers treatments that can make adherence more visible: an injection given is easier to document than a tablet hoped for. For clinicians, it offers multiple dosing rhythms and support around access. For pharmaceutical partners, the legacy proposition is different - formulation know-how that can improve how an existing active ingredient behaves. None of these removes the clinical tradeoffs. They do explain why the company's expertise extends beyond finding a promising molecule.
A company edited down
The modern Alkermes emerged through subtraction as much as addition. In 2023 it separated its oncology business into Mural Oncology. It later sold its Athlone manufacturing operation. The result was a cleaner neuroscience story supported by three sites: global headquarters in Dublin, an R&D and corporate hub in Waltham, Massachusetts, and manufacturing in Wilmington.
Nearly 600 people work at the Waltham site, where laboratories sit alongside commercial, medical and corporate functions. Across the company, head count reached about 2,050 after the Avadel acquisition. Alkermes says its culture is built on compassion, collaboration, responsibility and respect for each voice. Five employee resource groups cover disability and illness, multicultural community, veterans, LGBTQ+ colleagues and women. The language may sound familiar in biotech; the 2025 voluntary attrition rate of 7 percent gives it a measurable edge.
“With a strong commercial business, an exciting pipeline, a deeply committed team, and a clear path for growth, I'm energized by the opportunities ahead.”Blair Jackson, CEO
Jackson took the chief executive role on August 1, following Richard Pops' 35 years in the job. Pops remains chairman. Few public biotech handoffs carry that much institutional memory. Jackson has been inside Alkermes for more than two decades and helped execute the oncology separation, the Athlone sale and the Avadel purchase. This is succession as continuity, not rebellion.
Where the bet can break
Every neat strategy sits on untidy risks. Alixorexton can fail a late-stage study or reveal safety problems that smaller trials could not show. LUMRYZ competes in a market led by Jazz and carries the operational burden of a restricted distribution program. VIVITROL faces expected generic competition. Payers can demand discounts, physicians can prefer familiar options and manufacturing failures can turn a good quarter into a supply problem.
Debt from the Avadel acquisition adds pressure to execute. Alkermes expects the acquired business to improve earnings, but integration, revenue growth and debt repayment are outcomes, not facts. Meanwhile, a company that sells established medicines must keep funding trials whose returns may be years away. The portfolio is a bridge between certainty and possibility, with toll collectors at both ends.
Still, Alkermes occupies a useful middle ground in neuroscience. It is large enough to discover, formulate, manufacture and sell a medicine, but focused enough that one receptor family can reshape the company. It serves markets many drug makers historically treated as difficult: addiction shaped by stigma, psychosis complicated by adherence, sleep disorders that are easy to trivialize and exhausting to live with.
The old Alkermes asked how long a medicine could keep working. The new one is asking how wakefulness itself works - and whether understanding that switch can support not one product, but a franchise. The answer will come in trial readouts, prescriptions and mornings that patients can actually use.